commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than May 6, 1996.

A. Federal Reserve Bank of Atlanta (Zane R. Kelley, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303:

1. Bradley County Financial Corp., Cleveland, Tennessee; to engage *de novo* through its subsidiary, Tennessee Financial Services, Inc., Cleveland, Tennessee, in consumer finance and insurance agency activities, pursuant to §§ 225.25(b)(1)(i) and 225.25(b)(8)(ii) of the Board's Regulation Y. The proposed activities will be conducted throughout the States of Tennessee and Georgia.

B. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. Norwest Corporation, Minneapolis, Minnesota; to acquire Bancshares Life Insurance Company, San Antonio, Texas, and thereby engage in sales and underwriting of credit life, credit accident, and credit health insurance, pursuant to § 225.25(b)(8)(1) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, April 16, 1996.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 96–9809 Filed 4–19–96; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made final findings of scientific misconduct in the following case:

Joan Gans, R.N., Denver Department of Health and Hospitals: Based on an audit of records conducted by the National Institute of Allergy and Infectious Diseases (NIAID) and Ms. Gans— admission, ORI found that Joan Gans, R.N., while employed at the Denver Community Program for Clinical Research on AIDS at the Department of Public Health, Denver Department of Health and Hospitals, committed scientific misconduct by falsifying and fabricating data related to patients entered on clinical trials. The research was supported by a NIAID contract.

Ms. Gans has entered into a Voluntary Exclusion Agreement with ORI in which she has voluntarily agreed:

(1) To exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government, as defined in 45 CFR Part 76 (Debarment Regulations) for a period of two (2) years beginning April 4, 1996;

(2) That for a period of one (1) year immediately following the two (2) year voluntary exclusion above, any institution that submits an application for Public Health Service (PHS) support for a research project on which Ms. Gans' participation is proposed or that uses her in any capacity in PHS supported research must concurrently submit a plan for supervision of her duties; the supervisory plan must be designed to ensure the scientific integrity of Ms. Gans' research contribution, and the institution must submit a copy of the plan to ORI; and

(3) To exclude herself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) years beginning April 4, 1996.

The above voluntary exclusion, however, shall not apply to Ms. Gans' future training or practice of clinical nursing whether as a nursing student, resident, fellow, or licensed nurse, as the case may be, unless that practice involves research or research training.

No scientific publications were required to be corrected as part of this Agreement. The questioned data will be excluded before any findings of the affected clinical trials are reported.

FOR FURTHER INFORMATION CONTACT: Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 96–9778 Filed 4–19–96; 8:45 am]

BILLING CODE 4160–17–P

Administration for Children and Families

Agency Recordkeeping/Reporting Requirements Under Emergency Review by the Office of Management and Budget (OMB)

Title: ACF Uniform Discretionary Grant Application Form.

OMB No.: New.

Description: ACF has more than thirty discretionary grant programs. The proposed information collection form would be a uniform discretionary application form usable for all of these grant programs to collect the information from grant applicants needed to evaluate and rank applicants and protect the integrity of the grantee selection process. All ACF discretionary grant programs would be eligible but not required to use this application form. The application consists of general information and instructions; the Standard Form 424 series that requests basic information, budget information and assurances; the program application requesting the applicant to describe how these objectives will be reached; and certifications. Guidance for the content of information requested in the program application is found in OMB Circulars A–102 and A–110.

Respondents; Not-for-profit institutions, State, Local and Tribal Govt.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Application Form	4,418	1	4	17,672

Estimated Total Annual Burden Hours: 17,672.

Additional Information: ACF is requesting that OMB grant a 90 day approval for this information collection under procedures for emergency processing by April 17, 1996. A copy of this information collection, with applicable supporting documentation, may be obtained by calling the

Administration for Children and Families, Reports Clearance Officer, Roberta Katson at (202) 401–5756.

Comments and questions about the information collection described above should be directed to the Office of Information and Regulatory Affairs, Attn: OMB Desk Officer for ACF, Office of Management and Budget, Paperwork Reduction Project, 725 17th Street NW., Washington, DC 20503, (202) 395–7316.

Dated: April 10, 1996.

Roberta Katson,

Director, Office of Information Resource Management Services.

[FR Doc. 96–9750 Filed 4–19–96; 8:45 am]

BILLING CODE 4184–01–M

[Program Announcement No. ACF/ACYF/ RHYP 96–2]

Runaway and Homeless Youth Program (RHYP): Fiscal Year (FY) 1996 Final Program Priorities, Availability of Financial Assistance for Fiscal Year 1996, and Request for Applications for FY 1996 and FY 1997

AGENCY: Family and Youth Services Bureau (FYSB), Administration on Children, Youth and Families (ACYF), Administration for Children and Families (ACF), Department of Health and Human Services (HHS).

ACTION: Extension of due date for receipt of applications for the Basic Center Program for Runaway and Homeless Youth (BCP) for FY 1996.

SUMMARY: This notice amends program announcement number ACF–ACYF–RHYP–96–2 published in the Federal Register on April 15, 1996 by extending the due date for submission of the BCP applications to June 7, 1996. This notice does not affect the due date for TLP applications. That date remains June 14, 1996.

FOR FURTHER INFORMATION CONTACT: Administration on Children, Youth and Families, Family and Youth Services Bureau, P.O. Box 1182, Washington, DC 20013; Telephone: 1–800–351–2293.

SUPPLEMENTARY INFORMATION: Under Part A of the Runaway and Homeless Youth Act, as amended, the overall purpose of the Basic Center Program is to provide financial assistance to establish or strengthen community-based centers that address the immediate needs (outreach, temporary shelter, food, clothing, counseling, aftercare, and related services) of runaway and homeless youth and their families.

(Catalog of Federal Domestic Assistance. Number 93.623, Basic Center Program for Runaway and Homeless Youth; Number 93.550)

Dated: April 16, 1996.

Olivia A. Golden,

Commissioner, Administration on Children, Youth and Families.

[FR Doc. 96–9861 Filed 4–19–96; 8:45 am]

BILLING CODE 4184–01–M

President's Committee on Mental Retardation; Notice of Meeting

AGENCY HOLDING THE MEETING: President's Committee on Mental Retardation.

TIME AND DATE: Full Committee Meeting, May 24, 1996, 10:00 a.m.–4:00 p.m.

PLACE: Hyatt Regency Washington on Capitol Hill, 400 New Jersey Avenue, NW., Washington, DC 20001.

STATUS: Meetings are open to the public. An interpreter for the deaf will be available upon advance request. All locations are barrier free.

TO BE CONSIDERED: The Committee plans to discuss critical issues concerning Federal Policy, Federal Research and Demonstration, State Policy Collaboration, Minority and Cultural Diversity and Mission and Public Awareness.

THE PCMR acts in an advisory capacity to the President and the Secretary of the U.S. Department of Health and Human Services on a broad range of topics relating to programs and services for persons with mental retardation. The Committee, by Executive Order, is responsible for evaluating the adequacy of current practices in programs for persons with mental retardation, and for reviewing legislative proposals that impact the quality of life that is experienced by citizens with mental retardation and their families.

CONTACT PERSON FOR MORE INFORMATION: Gary H. Blumenthal, Wilbur J. Cohen Building, Room 5325, 330 Independence Avenue, SW., Washington, DC 20201–0001, (202) 619–0634.

Dated: April 16, 1996.

Gary H. Blumenthal,

Executive Director, PCMR.

[FR Doc. 96–9860 Filed 4–19–96; 8:45 am]

BILLING CODE 4184–01–M

Food And Drug Administration

[Docket No. 95N–0308]

Inapplicability of the Dietary Supplement Health and Education Act to Animal Products

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is providing guidance regarding the inapplicability of the Dietary Supplement Health and Education Act of 1994 (the DSHEA) to products intended for use in animals. The agency is issuing this notice in response to inquiries received on whether the DSHEA applies to products intended for use in animals.

DATES: Submit written comments by July 22, 1996.

ADDRESSES: Written comments may be submitted to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857. Comments should be identified with the docket number found in brackets in the heading of this document. Received comments may be seen at the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Donny Dean, Center for Veterinary Medicine (HFV–236), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1726.

SUPPLEMENTARY INFORMATION: FDA has had inquiries concerning whether the DSHEA applies to products intended for use in animals. After examining the statutory language, intent, and legislative history, the agency has determined that the DSHEA does not apply to animal products.

On October 25, 1994, the DSHEA (Pub. L. 103–417) was signed into law. The DSHEA amends the Federal Food, Drug, and Cosmetic Act (the act) to create a new regulatory scheme for ''dietary supplements.'' The DSHEA, among other things, amended the act by adding section 201(ff) (21 U.S.C. 321(ff)), which defines a ''dietary supplement,'' in part, as a product, other than tobacco, intended to supplement the diet that contains at least one or more of the following ingredients: A vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of any of the previously